Business
Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034
Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.c
About this update from Eli Lilly And Company
[{"type":"image","alt":"Company Logo","displaySize":"","headline":null,"caption":"Company Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":36,"url":"https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g_3H8YP5.WdAX5cBtX03VA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6a90a26a88cc04ec0d3fe15e0ab1be65","width":300,"height":36}},"lazy":false},{"type":"text","content":"Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth.","length":337,"tagName":"p"},{"type":"text","content":"Abemaciclib Market","length":18,"tagName":"p"},{"type":"image","alt":"Abemaciclib Market","displaySize":"","headline":null,"caption":"Abemaciclib Market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height":400,"url":"https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vSaoJaeXNtgf00dOZrcoaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ddda3a59e715735ec1b7407ff5a69bde","width":600,"height":400}}},{"type":"text","content":"Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The abemaciclib market size has grown rapidly in recent years. It will grow from $1.42 billion in 2024 to $1.6 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth during the historic period was driven by increasing clinical trial success rates for CDK4 and CDK6 inhibitors, growing adoption of targeted therapies in oncology, rising use of adjuvant therapy in early breast cancer, expanded availability of companion diagnostics, and increased patient advocacy and awareness campaigns. ","length":664,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":600,"height...